HDAC2 and early-onset autosomal dominant Alzheimer disease: Inhibition of HDAC2 is beneficial in the amelioration of neurodegenerative pathologies in Alzheimer’s disease (AD) [28], Parkinson’s disease (PD) [29], and ischemic stroke [30].